1. Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era
- Author
-
Alan Wells, Maggie Blake, Mounzer Agha, Ghady Haidar, and Charles Chilleo
- Subjects
0301 basic medicine ,Coronavirus disease 2019 (COVID-19) ,Chronic lymphocytic leukemia ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,media_common.quotation_subject ,CoV ,medicine.disease_cause ,Immunoglobulin G ,03 medical and health sciences ,0302 clinical medicine ,antibody ,medicine ,Coronavirus ,media_common ,COVID ,SARS ,Messenger RNA ,hematological malignancy ,biology ,business.industry ,medicine.disease ,030104 developmental biology ,Infectious Diseases ,AcademicSubjects/MED00290 ,Oncology ,030220 oncology & carcinogenesis ,19 vaccine ,Immunology ,biology.protein ,Brief Reports ,Antibody ,business ,Vigilance (psychology) - Abstract
Studies describing SARS-CoV-2 immune responses following mRNA vaccination in hematology malignancy (HM) patients are virtually non-existent. We measured SARS-CoV-2 IgG production in 67 HM patients who received 2 mRNA vaccine doses. We found that 46% of HM patients did not produce antibodies and were therefore vaccine non-responders. Patients with B-cell CLL were at a particularly high risk, as only 23% had detectable antibodies despite the fact that nearly 70% of these patients were not undergoing cancer therapy. HM patients should be counseled about the ongoing risk of COVID-19 despite vaccination. Routine measurement of post-vaccine antibodies in HM patients should be considered. Novel strategies are needed to prevent COVID-19 in these individuals.
- Published
- 2021